Surgery Websites
MacKenzie Lab »  People »  Lab Members »  Akos Herzeg, M.D., Ph.D., MBA
Akos Herzeg, M.D., Ph.D., MBA

Akos Herzeg, M.D., Ph.D., MBA

  • Research Fellow

Contact Information

35 Medical Center Way, #903D
San Francisco, CA 94143
Open Popup

Akos Herzeg, MD, PhD, MBA - Research Fellow is a German/Hungarian Maternal-Fetal Medicine specialist and a fetal surgeon. He is the inaugural senior fellow in the MacKenzie Lab and UCSF Center for Maternal-Fetal Precision Medicine where he is working closely with Tippi Mackenzie, on clinical applications of fetal molecular therapies: fetal gene therapies and fetal enzyme replacement therapies. Akos has trained in prenatal medicine and fetal therapy at the University of Heidelberg in Germany where he has led the development and clinical oversight of the Center for Fetal Surgery. His expertise includes managing complicated monochorionic twins, complex multiple gestations, high-risk pregnancies, and fetal Spinal dysraphisms. He also holds an MBA in Healthcare Administration with a concentration in the Management of Centers of Healthcare Excellence and is currently the Chief Strategy Officer of the UCSF Broad Stem Cell Center.

  Dept or School    
  End Date    
  • Heidelberg University, Heidelberg
  • OBGYN Specialist
  • 07/2015
  • Heidelberg University, Heidelberg
  • PhD
  • Molecular Biology
  • 06/2015
  • Semmelweis University, Budapest
  • MD
  • Medicine
  • 09/2007
  • MIT, Boston, MA
  • Artificial Intelligence in Healthcare
  • 12/2022
  • Frankfurt School of Finance and Management, Frankfurt
  • MBA
  • Healthcare Business Administration
  • 05/2019
  • Heidelberg University, Heidelberg
  • Fellowship Maternal Fetal Medicine
  • 07/2017
  • UCSF, San Francisco
  • Postdoc Research Epidermal Stem Cells
  • 05/2010
  • Hatieganu Medical University, Cluj Napoca
  • MD
  • Medicine
  • 09/2007
  •   Award  
      Confired By    
  • Alumni Scholarship
  • Frankfurt School of Finance and Management
  • 2017 - 2019
    Data provided by UCSF Profiles, powered by CTSI
    1. Herzeg A, Almeida-Porada G, Charo RA, David AL, Gonzalez-Velez J, Gupta N, Lapteva L, Lianoglou B, Peranteau W, Porada C, Sanders SJ, Sparks TN, Stitelman DH, Struble E, Sumner CJ, MacKenzie TC. Prenatal Somatic Cell Gene Therapies: Charting a Path Toward Clinical Applications (Proceedings of the CERSI-FDA Meeting). J Clin Pharmacol. 2022 09; 62 Suppl 1:S36-S52. View in PubMed
    2. Mouzakiti N, Sierra F, Herzeg A, Al Naimi A, Reising C, Bahlmann F, Kyvernitakis I. The impact of a short cervix and funneling on the outcome in singleton pregnancies treated with an Arabin-pessary or a McDonald cerclage. J Matern Fetal Neonatal Med. 2021 Aug; 34(15):2491-2497. View in PubMed
    3. Wolnicki BG, von Wedel F, Mouzakiti N, Al Naimi A, Herzeg A, Bahlmann F, Kyvernitakis I. Combined treatment of McDonald cerclage and Arabin-pessary: a chance in the prevention of spontaneous preterm birth? J Matern Fetal Neonatal Med. 2020 Oct; 33(19):3249-3257. View in PubMed
    4. Szabo AZ, Bocsan IC, Suciu S, Buzoianu AD. Comparative animal study of the antinociceptive efficacy of lamotrigine and gabapentin for the management of pain. Acta Physiol Hung. 2015 Dec; 102(4):363-71. View in PubMed
    5. Maierthaler M, Kriegsmann M, Peng C, Jauch S, Szabo A, Wallwiener M, Rom J, Sohn C, Schneeweiss A, Sinn HP, Yang R, Burwinkel B. S100P and HYAL2 as prognostic markers for patients with triple-negative breast cancer. Exp Mol Pathol. 2015 Aug; 99(1):180-7. View in PubMed
    6. View All Publications


    Site Directory